Merck & Co. generated $65.8B in trailing twelve-month revenue, up 0.0% year-over-year. Net income was $8.9B with a 13.59% net margin. Diluted EPS is $3.56, which declined 0.5% year-over-year. Based on the Q1 2026 filing.